Thursday , August 17 2017
Home / Biosimilars / Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira

Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira

Check Also

Biosimilars Forum Applauds Senator Passage of the FDA Reauthorization Act

Washington, D.C. (August 3, 2017) – Today, the Biosimilars Forum issued the following statement on …